Evolution in the Management of Oligometastatic Prostate Cancer: What Does the Evidence Show When Selecting the Treatment of Choice?
Evolution in the Management of Oligometastatic Prostate Cancer: What Does the Evidence Show When Selecting the Treatment of Choice?
Speakers: Alejandro Berlin, Frédéric Pouliot & Ricardo Rendon
Objectives
By the end of this program, participants can expect to:
- Understand the treatment options for de novo, castrate-sensitive, and castrate-resistant oligometastatic prostate cancer.
- Differentiate between length of therapy and duration of testosterone suppression for optimal patient outcomes.
- Discuss the application of evidence-based medicine in determining the place of various treatment options through patient cases.
ACCREDITATION
This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.
This program has received financial support from TerSera in the form of an educational grant.